Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. It operates through the following business divisions: Novel drug development and Cell culture media manufacturing. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seongnam-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company